Status:
COMPLETED
A Study of Effect of Megakaryocytes and Platelets in Breast Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Determining if Megakaryocytes and Platelets are Harmful or Helpful in Breast Cancer Cell Metastasis
Detailed Description
The purpose of this study is to determine how megakaryocytes (cells in the bone marrow responsible for making platelets, which are necessary for blood clotting) affect the survival and growth/division...
Eligibility Criteria
Inclusion
- Cohort 1-Biopsy negative
- Females age 18 and above
- Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
- Females age 18 and above
- Any subtype of breast cancer
- Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
- Females age 18 and above
- Any subtype of breast cancer
- Have no distant metastases
- Cohort 4-Stage 4 Metastatic Disease
- Females age 18 and above
- Any subtype of breast cancer
Exclusion
- Previous diagnosis with a known platelet disorder such as: Bernard Soulier disease, Jacobsen syndrome, Lowe syndrome, Thrombocytopenia, Thrombotic thrombocytopenic pupura, Von Willebrand disease, or the equivalent. Any condition in which antiplatelet or anticoagulant therapy with one of the following medications is being prescribed: Clopidogrel (Plavix), Warfarin (Coumadin or Jantoven), Prasugrel (Effient), or Ticagrelor (Brilinta).
- Cohort 1-Biopsy negative
- Males
- Females less than age 18
- Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
- Males
- Females less than age 18
- Currently undergoing neoadjuvant therapy
- Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
- Males
- Females less than age 18
- Presence of distant metastases
- Currently undergoing neoadjuvant therapy
- Cohort 4-Stage 4 Metastatic Disease
- Males
- Females less than age 18
- Currently undergoing neoadjuvant therapy
- Less than 30 days from last adjuvant treatment for Stage I-III Breast Cancer (may be on Trastuzumab, Pertuzumab, or endocrine therapy only for maintenance therapy from their prior breast cancer diagnosis)
Key Trial Info
Start Date :
August 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 29 2025
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06011824
Start Date
August 29 2023
End Date
April 29 2025
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States, 54601